1. Home
  2. RBOT vs LNAI Comparison

RBOT vs LNAI Comparison

Compare RBOT & LNAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vicarious Surgical Inc.

RBOT

Vicarious Surgical Inc.

HOLD

Current Price

$1.99

Market Cap

17.9M

Sector

Health Care

ML Signal

HOLD

Logo Lunai Bioworks Inc.

LNAI

Lunai Bioworks Inc.

N/A

Current Price

$0.39

Market Cap

18.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RBOT
LNAI
Founded
2014
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.9M
18.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
RBOT
LNAI
Price
$1.99
$0.39
Analyst Decision
Hold
Analyst Count
2
0
Target Price
$7.00
N/A
AVG Volume (30 Days)
62.8K
294.4K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.71
$0.38
52 Week High
$13.75
$1.66

Technical Indicators

Market Signals
Indicator
RBOT
LNAI
Relative Strength Index (RSI) 45.88 30.10
Support Level $1.76 N/A
Resistance Level $2.41 $1.06
Average True Range (ATR) 0.20 0.10
MACD 0.03 -0.03
Stochastic Oscillator 40.78 3.71

Price Performance

Historical Comparison
RBOT
LNAI

About RBOT Vicarious Surgical Inc.

Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port. The company has following segment: Research and development, Sales and marketing, General and administrative.

About LNAI Lunai Bioworks Inc.

Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.

Share on Social Networks: